2025-11-20 – Press Releases – www.prnewswire.com
MELBOURNE, Australia and INDIANAPOLIS, Nov. 20, 2025 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces results from the ZIRCON-X study which finds that almost half of all patients imaged with TLX250-CDx (Zircaix®[1], 89Zr-DFO-girentuximab)…
